Le Lézard
Classified in: Health, Science and technology
Subjects: Conference, Webcast

Pulse Biosciences to Present at the Stifel 2021 Virtual Healthcare Conference


Pulse Biosciences, Inc. (Nasdaq: PLSE), a novel bioelectric medicine company introducing the CellFX® System powered by Nano-Pulse Stimulationtm (NPStm) technology, today announced that members of management will present at the Stifel 2021 Virtual Healthcare Conference on Wednesday, November 17, 2021 at 1:40pm PT / 4:40pm ET.

Interested parties may access the on-demand webcast at the same time on the "Investors" section of the Company's website at www.pulsebiosciences.com.

About Pulse Biosciences®

Pulse Biosciences is a novel bioelectric medicine company committed to health innovation that has the potential to improve the quality of life for patients. The Company's proprietary Nano-Pulse Stimulationtm (NPStm) technology delivers nano-second pulses of electrical energy to non-thermally clear cells while sparing adjacent non-cellular tissue. The CellFX® System is the first commercial product to harness the distinctive advantages of NPS technology to treat a variety of applications for which an optimal solution remains unfulfilled. The initial commercial use of the CellFX System is to address a range of dermatologic conditions that share high demand among patients and practitioners for improved dermatologic outcomes. Designed as a multi-application platform, the CellFX System offers customer value with a utilization-based revenue model. Visit pulsebiosciences.com to learn more.

To stay informed about the CellFX System, please visit CellFX.com and sign-up for updates.

Pulse Biosciences, CellFX, Nano-Pulse Stimulation, NPS and the stylized logos are among the trademarks and/or registered trademarks of Pulse Biosciences, Inc. in the United States and other countries.


These press releases may also interest you

at 18:00
Curio Digital Therapeutics Inc. Announces the U.S. Food and Drug Administration (FDA) Clearance of MamaLift Plustm, the First Prescription Digital Therapeutic Authorized for the Treatment of Postpartum Depression (PPD)
Curio Digital Therapeutics Inc. announced that the U.S. Food and Drug Administration (FDA) has granted clearance to MamaLift PlusTM. MamaLift Plus is the first prescription digital therapeutic for the treatment of postpartum depression (PPD), a...

at 17:45
BioSyent to Attend Planet MicroCap Showcase
BioSyent Inc. ("BioSyent", TSX Venture: RX) is pleased to announce that it will be attending the Planet MicroCap Showcase in Las Vegas, Nevada between April 30th ? May 2nd at the Paris Hotel & Casino. Mr. René Goehrum, President and CEO of BioSyent,...

at 17:44
Honoring Audrey Beverly Christy Mastroianni at United Breast Cancer Foundation's Mattress and Pink Bag Event: "Gifts of Comfort and Hope" in Warwick, Rhode Island
United Breast Cancer Foundation (UBCF) is proud to host a heartfelt event dedicated to honor the memory of Audrey Beverly Christy Mastroianni, a remarkable Rhode Island woman who bravely battled breast cancer. The "Gifts of Comfort and Hope" Mattress...

at 17:31
DRI Healthcare Trust Closes Previously Announced Refinancing of Preferred Securities
DRI Healthcare Trust (the "Trust") announces the closing of its previously announced preferred securities refinancing, whereby its US$114,760,000 aggregate principal amount of Series A and Series B preferred securities and 6,369,180 warrants were...

at 17:31
Global Corneal Implant Market is Expected to Showcase a Significant Growth at a CAGR of ~6% by 2030 | DelveInsight
DelveInsight's Corneal Implant Market...

at 17:26
Inception Fertilitytm & The Prelude Network® Tell Aspiring Parents 'We Get You, So We Got You' to Humanize the Fertility Experience
In observance of National Infertility Awareness Week (April 21-27, 2024), Inception Fertilitytm, a global leader of fertility services, and The Prelude Network®, Inception's clinical network and the largest network of fertility providers in North...

More news about Health...


News published on and distributed by: